NDAORALFOR SUSPENSION
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
INZIRQO (hydrochlorothiazide) by Teva is reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. First approved in 2025.
Drug data last refreshed 50m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INZIRQO is a thiazide diuretic oral suspension formulation of hydrochlorothiazide approved in January 2025. It reduces blood pressure by inhibiting sodium and chloride reabsorption in the distal convoluted tubule, thereby increasing urinary excretion and reducing plasma volume. This is a newly approved, conventionally available antihypertensive indicated for hypertension management.
Growth17.6 years to LOE
Early-stage growth product with 17.6 years of patent protection; commercial team is scaling post-launch with opportunity to establish market position in the generic-heavy diuretic space.
Mechanism of Action
reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary…
Pharmacologic Class:
Thiazide Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma
Started Dec 2023
42 enrolled
Healthy Participants
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice
Started Jun 2022
0Hypertension
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
Started Sep 2018
0HypertensionDiabetes Mellitus, Type 2
A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide
Started Jan 2018
16 enrolled
Type 2 Diabetes Mellitus
Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions
Started Mar 2017
42 enrolled
Hypertension
Worked on INZIRQO at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.